Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of adverse reactions… Click to show full abstract
Patients with severe thrombocytopenia due to bone marrow failure and after chemotherapy are still treated with platelet transfusions. Platelet concentrates (PC) are associated with a high incidence of adverse reactions (AR). Plateletāderived damageāassociated molecular patterns (DAMPS) and complement were proposed to play a role in the pathology of AR.
               
Click one of the above tabs to view related content.